Maybe BMS should stop funding Plavix studies
As reported earlier, BMS gave itself another black eye with a post-marketing study that ended up making its drug, Plavix, look bad compared with aspirin under certain conditions. Patients read about these studies in the paper or hear about them on TV at a superficial level. The natural reaction is to worry and even stop taking their medication.
The American College of Cardiology is worried that Plavix takers will abandon their prescriptions, and has issued an advisory telling patients not to stop taking Plavix without talking to their physician. In particular, patients with drug-eluting stents who stop taking Plavix put themselves at serious risk.
So please, BMS, be more careful next time you try one of these clever studies.March 20, 2006